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Lymph node metastatic involvement persists to be among the most important predictors of recurrence and survival in breast
carcinoma (BC). This study is aimed at investigating possible gene expression differences in primary BC between patients with
or without lymph node involvement at the time of diagnosis. In a retrospective study, we investigated the potential prognostic
role of 9 candidate biomarkers at the mRNA level in a cohort of 305 breast cancer patients, 151 lymph node-negative (LN-) and
154 lymph node-positive (LN+) individuals. The analyzed genes belonged to the RAS pathway (RAF1, ERBB2, PIK3CB, AKT1,
AKT2, and AKT3), RB pathway (RB1 and CDK2), and cellular differentiation (KRT8). Their expression profiles were
investigated by RT-qPCR and were correlated to immunohistochemically based molecular subtypes and BC clinical and
pathological features. The differential expression of several genes in the primary tumor tissue was related to the LN involvement.
Some of those genes, including PIK3CB, RB1, and AKT3, were more expressed in LN- BC patients, while some others, notably
ERBB2 and AKT1, in LN+ ones. Among the candidate biomarkers, the expression levels of AKT isoforms influenced also
patients’ survival rates. In detail, higher expression levels of AKT1 and AKT2 negatively influenced overall patients’ survival,
and in particular, AKT2 expression levels defined a group of luminal B BC patients with shorter cancer-specific survival. On the
contrary, longer cancer-specific survival was recorded in luminal A BC patients with higher expression levels of AKT3. That
finding was also confirmed by Cox multivariate analysis. The same AKT3 resulted to be a possible candidate predictive
biomarker for Tamoxifen response. In conclusion, our study highlighted the complex regulation of the PI3K/AKT pathway in
BC and its differences in BC patients with and without lymph node involvement.
1. Background
Breast carcinoma (BC) encompasses a heterogeneous group
of tumors with high variability at the molecular and morpho-
logical levels and clinical outcome [1, 2]. In the last few
decades, advances have been made in BC detection and ther-
apy through gene expression profiling, which has highlighted
BC molecular complexity and has increased prognostication
[3]. Subclassification of breast cancers into intrinsic subtypes
has assisted in determining the need for adjuvant chemother-
apy, particularly in patients with ER-positive diseases. In
most hospitals worldwide, the clinical management of BC is
mainly based on clinical-pathological features and the assess-
ment of few surrogate biomarkers, namely, the estrogen
receptor (ER), the progesterone receptor (PR), the human
epidermal growth factor receptor-2 (ERBB2), and Ki67. The
intrinsic BC subtypes have proven to be helpful for therapy
decisions for node-negative ER+ breast cancer patients, espe-
cially with tumors grade 2 and stage 2.
Clinical variables, such as the nodal status and tumor
size, remain highly clinically relevant even in the era of geno-
mic testing and are likely to remain important also for eval-
uating the risk of relapse for patients with BC [4]. Although
there is a strong association between molecular subtypes of
BC and prognosis, a significant number of patients show
similar features with distinct outcomes. It is estimated that
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30–50% of patients with early to locally advanced breast can-
cer at diagnosis experience relapse, despite the use of adju-
vant systemic treatment after surgery [5]. One of the major
concerns regarding the utility of BC intrinsic subtypes is that
BC prognostication is mainly addressed to young women at
an early tumor stage, without lymph node involvement or
with a maximum of 3 positive lymph nodes, so there is a lack
of information for patients with a higher tumor stage.
In the present study, we have evaluated the mRNA
expression profiles of 9 genes, 7 of which were tested in BC
in other studies by our group [6, 7], in a cohort of young
women aged 55 or less, both lymph node negative (LN-)
and lymph node positive (LN+). The analyzed genes belong
to signaling pathways that control major cellular processes,
such as cell cycle regulation and the PI3K/AKT/TOR signal-
ing pathway.
The genes analyzed in the present study are phos-
phatidylinositol 3 kinase (PIK3CB-p110β), v-AKT murine
thymoma viral oncogene homolog 1 (AKT1), v-AKT murine
thymoma viral oncogene homolog 2 (AKT2), v-AKT murine
thymoma viral oncogene homolog 3 (AKT3), v-RAF-1
murine leukemia viral oncogene homolog 1 (RAF1), and
keratin 8 (KRT8). The aim of this study is to investigate the
possible impact of those genes in BC prognostication and
characterization for lymph node involvement, the molecular
subtyping, the clinical and pathological features, and a long
follow-up period.
2. Methods
2.1. Patients. This is a population-based retrospective study.
All patients resided in a province in the northeastern area
of Italy. Inclusion criteria were (i) diagnosis of BC at least
15 years before the censoring date of the study (31st of
December 2008), (ii) invasive BC of stages I-III, (iii) age
at diagnosis 55 years or younger, and (iv) availability of
formalin-fixed and paraffin-embedded (FFPE) tissues. Cases
with second primary breast cancer or other malignancies
were excluded from the study. The patients enrolled and
analyzed in the present study were characterized in a previ-
ous study through microarray analysis with immunohisto-
chemical detection of ER, PR, Ki67, KRT8, KRT5/6, and
vimentin [8].
The cohort included 305 patients; of these, 154 (50.4%)
had lymph node involvement (LN+) at diagnosis. FFPE tis-
sues of the primary tumor obtained by surgical treatment
were used for molecular analysis. Clinical information was
obtained from medical records. Tumors were reviewed, his-
tologically and molecularly classified as already reported
[8]. Classification of luminal A and B BC has been corrected
based on the St. Gallen 2013 Consensus that recommended
to use a cutoff of Ki67 < 20% for luminal A BC [9]. The
patients’ cohort was followed for a maximum of 25 years
through the local cancer registry from diagnosis of BC to
death or until the censoring date. This study was approved
by the Ethical Committee of the University of Trieste as
already described [8, 10]. Follow-up data were reported in
previous studies [8, 10].
Briefly, patients were treated with mastectomy or breast-
conserving surgery. All LN+ patients were treated with
adjuvant chemotherapy regimens according to standard
protocols as already reported [8]. ER-positive patients were
submitted to hormone therapy with Tamoxifen. No specific
treatment with trastuzumab was performed in HER2-
positive patients because that therapy was not available at
the time of diagnosis. Patients’ clinical and pathological var-
iables are reported in Table 1.
2.2. Gene Expression Profiling. The potential prognostic role
of the 9 genes of interest was investigated by quantitative
real-time PCR (qPCR). Briefly, total RNA was extracted from
FFPE tissues after manual microdissection as previously
described [11]. For each sample, 4 μg of total RNA was
treated with DNase as already described [12].
Complementary DNA (cDNA) synthesis was performed
using 1.2 μg of RNA and the Moloney murine leukemia
virus (M-MLV) reverse transcriptase (Invitrogen, Karlsruhe,
Germany) by random hexamer priming in a final volume of
20μl, as described in detail elsewhere [13].
Expression levels of RB1, CDK2, ERBB2, PIK3CB, AKT1,
AKT2, AKT3, RAF1, and KRT8 were analyzed by qPCR
using a Mastercycler® ep realplex (Eppendorf, Hamburg,
Germany). PCR assays were performed in duplicate using
TaqMan probes and the JumpStart™ Taq ReadyMix™ for
quantitative PCR (Sigma-Aldrich, St. Louise, USA) according
to the manufacturer’s instructions. cDNA (30 ng for ACTB,
CDK2, ERBB2, and AKT3; 40 ng for RAF1; 50 ng for
AKT2; and 60ng for RB1, PIK3CB, and AKT1) was amplified
in a final volume of 20 μl. Cycle conditions were (i) a dena-
turation step for 10 minutes at 95°C and (ii) 45 two-step
cycles including 1 minute at 95°C for denaturation and 1
minute at 60°C for annealing-elongation. To exclude con-
tamination, negative controls without cDNA were included
in all analyses. RNA extracted from the breast cancer cell line
MCF-7 was used as a positive control. Primer and probe
sequences were created by the use of the Primer Express Soft-
ware (Applied Biosystems, Darmstadt, Germany), and they
are reported in Supplementary Table 1. Gene expression
levels were normalized using ACTB as the housekeeping
gene, while RNA from 6 samples of the cohort were pooled
and used as a calibrator. The relative quantification was
determined using the method proposed by Livak and
Schmittgen [14].
2.3. Statistical Analysis. The distribution of clinical-
pathological features between LN-/LN+ and over the four
molecular BC subtypes was investigated with the chi2 test.
The ratio of the investigated genes at the mRNA level among
lymph node involvement, the recurrence, and the molecular
classification was analyzed with the Kruskal-Wallis test
[15]. Spearman’s rank correlation coefficient was measured
to identify a possible correlation between protein and mRNA
expression levels of ERBB2. To assess a trend across the
ordered group, mRNA expression levels were submitted to
an extension of the Wilcoxon rank-sum test, developed by
Cuzick [16]. For survival analysis, the normalized ratios of
the analyzed genes were dichotomized accordingly to their
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Table 1: Clinical-pathological characteristics of breast cancers involved in this study.
Factors Total case study 305 (100%) LN- 151 (49.5%) LN+ 154 (50.5%)
Age (years)
≤35 21 (6.9%) 4 (2.6%) 17 (11.0%)
>35 284 (93.1%) 147 (97.4%) 137 (89.0%)
Mean age (years) (range) 46.9 (26-55) 46.8 (32-55) 47.0 (26-55)
Histology
Ductal 259 (84.9%) 118 (78.1%) 141 (91.6%)
Lobular 16 (5.2%) 9 (6.0%) 7 (4.5%)
Medullary 8 (2.6%) 8 (5.3) —
Mucinous 4 (1.3%) 3 (2.0%) 1 (0.6%)
Tubular 7 (2.3%) 7 (4.6%) —
Others 11 (3.6%) 6 (4.0%) 5 (3.2%)
Grade
1 39 (12.8%) 33 (21.9%) 6 (3.9%)
2 144 (47.2%) 86 (57%) 58 (37.7%)
3 119 (39.0%) 31 (20.5%) 88 (57.1%)
Unknown 3 (1.0%) 1 (0.7%) 2 (1.3%)
Tumor size (cm)
≤2 179 (58.7%) 107 (70.9%) 72 (46.8%)
2-5 100 (32.8%) 35 (23.2%) 65 (42.2%)
≥5 13 (4.3%) 1 (0.7%) 12 (7.8%)
Unknown 13 (4.3%) 8 (5.3%) 5 (3.2%)
Lymph nodes
1-3 lymph nodes 90 (29.5%) — 90 (58.4%)
≥4 lymph nodes 45 (14.8%) — 45 (29.2%)
Unknown 19 (6.2%) 19 (12.3%)
Stage
I 107 (35.1%) 107 (70.9%) —
II 125 (41.0%) 42 (27.8%) 83 (53.9%)
III 72 (23.6%) 2 (1.3%) 70 (45.5%)
Unknown 1 (0.3%) — 1 (0.6%)
Recurrence
No 143 (46.9%) 98 (64.9%) 45 (29.2%)
Yes 147 (48.2%) 49 (32.5%) 98 (63.6%)
Unknown 15 (4.9%) 4 (2.6%) 11 (7.1%)
ER
Negative 63 (20.7%) 25 (16.6%) 38 (24.7%)
Positive 242 (79.3%) 126 (83.4%) 116 (75.3%)
PR
Negative 81 (26.6%) 27 (17.9%) 54 (35.1%)
Positive 223 (73.1%) 123 (81.5%) 100 (64.9%)
Unknown 1 (0.3%) 1 (0.7%) —
ERBB-2
Negative 242 (79.3%) 139 (92.0%) 103 (66.9%)
Positive 61 (20.0%) 11 (7.3%) 50 (32.5%)
Unknown 2 (0.7%) 1 (0.7%) 1(0.6%)
Ki67
<20% 172 (56.4%) 108 (71.5%) 64 (41.6%)
≥20% 133 (43.6%) 43 (28.5%) 90 (58.4%)
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median value. In this way, patients with lower gene expres-
sion in comparison with the corresponding median were clas-
sified as having a lower status, while patients who presented
higher values were classified as having the higher status of
gene expression. The log-rank test was used to investigate
whether each molecular and clinical-pathological variable
affects the patients’ survival. Afterward, the Cox proportional
hazard regressionmethod was applied for the analysis of path-
ological covariates (histologic type, stage, and grade of the
tumor and age at diagnosis), molecular classification, and gene
expression levels in the entire cohort of patients, to test the
joint effects of the covariates on patients’ survival. All statisti-
cal analyses were two sided, and values of p < 0:05 were con-
sidered statistically significant, although the Kruskal-Wallis
test for more than two groups adjusted the significant value
to a value lower than 0.05.
Logistic regression and ROC postestimation were used
to predict lymph node involvement using the expression
levels of specific genes in primary BC. All the statistical
analyses were carried out with the package Stata/SE 12.0
(Stata, College Station, TX).
3. Results
3.1. Patients and Clinical-Pathological Tumor Characteristics.
In this cohort of 305 patients, 151 resulted to be negative for
axillary locoregional lymph node involvement (LN-) at the
time of diagnosis and 154 showed positive axillary locoregio-
nal lymph nodes (LN+) as already reported [8, 10]. Patients’
mean age at diagnosis was 47 years (range 26-55). No signif-
icant difference was detected for age at diagnosis between the
groups defined by lymph node involvement [8]. The mean
follow-up time was 14 years (range 0-25); in detail, it was
16 years (range 0-25) for the LN- group and 11 years (range
0-24) for the LN+ group. During the entire period of observa-
tion, 18 patients (6%) were lost at follow-up and 128 women
(42%) died from breast carcinoma; of those, 39 (30%) were
LN- and 89 (70%) were LN+. Recurrence was registered in
49 patients (33%) of the LN- group and 98 (69%) in the LN
+ group. For 15 patients (5%) (4 LN- and 11 LN+), no infor-
mation on the development of recurrences was found.
Molecular subtypes, as defined by immunohistochemis-
try (IHC) on the primary tumor, were as follows: 158 patients
(52%) were luminal A, 84 women (28%) were luminal B, 38
were triple negative (TN) (12%), and 24 were HER2 positive
(non-luminal) (8%) (Table 1). One case failed to be classified
in any molecular subtypes as already reported [8].
Histological classification, tumor differentiation, and
stage are reported in Table 1.
3.2. Relationship between Gene Expression and Clinical-
Pathological Data. The expression level of the mRNA of the
9 genes was investigated in relation to the following BC
clinical-pathological factors: histological type (ductal, lobu-
lar, medullary, mucinous, and tubular), tumor grade (1, 2,
and 3), tumor size (smaller than 2 cm, between 2 and 5 cm,
and larger than 5 cm), lymph node involvement (yes or no),
number of positive nodes (less or more than 3 lymph nodes)
tumor stage (I, II, and III), presence of later recurrence (yes
or no), age at diagnosis (younger or older than 35 years),
and patient status at the end of follow-up (alive or dead from
BC). A graphical summary of the results is reported in
Figure 1. Detailed results are described in the supplementary
file of the results.
3.3. Relationship between Gene Expression and Lymph Node
Involvement. Significant differences were found for eight
out of nine candidate biomarkers according to lymph node
involvement. In detail, the levels of expression of AKT2
(p < 0:001), AKT3 (p < 0:001), PIK3CB (p < 0:001), and
RB1 (p = 0:01) were significantly higher in LN- patients as
shown in Figure 2. Conversely, AKT1 (p < 0:001), CDK2
(p < 0:001), KRT8 (p < 0:001), and ERBB2 (p < 0:001) were
more expressed in LN+ patients, irrespective of the number
of involved lymph nodes (≤3 or >3) (Figure 3). Those results
were confirmed also considering ER-positive tumors only.
Logistic regression showed that AKT1 (p < 0:001), AKT3
(p = 0:009), ERBB2 (p = 0:002), PIK3CB (p < 0:001), and
RB1 (p = 0:04) can describe lymph node involvement in
our cohort (p < 0:001). A new variable was generated as a
linear combination of the RT-qPCR ratio of the abovemen-
tioned genes as follows: LN involvement = 0:11 ∗ ratioERBB
Table 1: Continued.
Factors Total case study 305 (100%) LN- 151 (49.5%) LN+ 154 (50.5%)
KRT8
Negative 28 (9.2%) 12 (7.9%) 16 (10.4%)
Positive 263 (86.2%) 134 (88.7%) 129 (83.8%)
Unknown 14 (4.6%) 5 (3.3%) 9 (5.8%)
KRT5/6
Negative 230 (75.4%) 107 (70.9%) 123 (79.9%)
Positive 70 (23.0%) 42 (27.8%) 28 (18.2%)
Unknown 5 (1.6%) 2 (1.3%) 3 (1.9%)
Vimentin
Negative 216 (70.8%) 97 (64.2%) 119 (77.3%)
Positive 60 (19.7%) 42 (27.8%) 18 (11.7%)
Unknown 29 (9.5%) 12 (7.9%) 17 (11.0%)
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Clinical and 
pathological data
AKT1 mRNA
expression levels 
AKT2 mRNA
expression levels 
AKT3 mRNA 
expression levels
CDK2 mRNA
expression levels 
ERBB2 mRNA
expression levels 
KRT8 mRNA
expression levels 
PIK3CB mRNA
expression levels 
RAF1 mRNA
expression levels 
RB1 mRNA
expression levels 
Age at diagnosis
(≤ 35) 
⇑ in older (> 35 y)
p = 0.02
⇑in older (> 35 y)
p = 0.01
Histologic type ⇑ ductal ⇓ tubular
p = 0.002
⇑ductal ⇓medullary
p < 0.001
⇑Lobular ⇓medullary
p < 0.001
Tumor grade
Decreasing with 
grade p = 0.002
Decreasing with 
grade p < 0.001
Decreasing with 
grade p < 0.001
Tumor size ⇑ in t ≤ 2 cm ⇓ 2 < t ≤5 cm p < 0.001
Increasing with size 
p = 0.01
Decreasing with size 
p = 0.001
Lymph node 
involvement ⇑LN+p = 0.0001 ⇓LN+p = 0.0003 ⇓LN+p = 0.0001 ⇑LN+p = 0.0001   ⇑LN+p = 0.0001 ⇑LN+p = 0.0001 ⇓LN+p = 0.0001 ⇓LN+p = 0.01
Tumor stage Decreasing with stage p < 0.001
Increasing with stage 
p < 0.001
Increasing with stage 
p < 0.001
Increasing with stage 
p < 0.001
Molecular subtypes ⇓HER2-⇑Lum. A, 
⇑Lum. B p < 0.006 
⇑Lum. A-⇓Lum. B, 
⇓HER2 p < 0.0001 
⇑Lum. B ⇓TN  
p = 0.02
⇑HER2 ⇓TN p = 0.002
⇑HER2+p < 0.004 ⇑Lum. A and Lum. B 
p < 0.004
⇑Lum. A-⇓Lum.B, ⇓
HER2 p < 0.001
ER IHC ⇑p = 0.005 ⇑p = 0.0001 ⇑p = 0.04
PR IHC ⇑p = 0.008 ⇑p = 0.0001 ⇑p = 0.001 ⇑p = 0.03
ERBB 2 IHC ⇑p = 0.01 ⇓p = 0.05 ⇓p = 0.0001 ⇑p = 0.0001 ⇓p = 0.04 ⇓p = 0.0002 ⇓p = 0.01
KRT5/6 IHC ⇓p = 0.01 ⇓p = 0.0001
KRT8 IHC ⇑p = 0.03 ⇑p = 0.0001
Ki67 IHC ⇓p = 0.0001 ⇓p = 0.0002 ⇓p = 0.03
Vimentin IHC ⇓p = 0.02 ⇓p = 0.0001 ⇓p = 0.0001 ⇓p = 0.02
Relapses ⇑relapse p = 0.02 ⇓relapse p = 0.01 ⇓relapse
p < 0.001 ⇑relapse p = 0.02
⇓relapse
p < 0.001 ⇓relapse p = 0.01
Living vs BC death ⇓living p = 0.01 ⇑living p = 0.02 ⇑living p < 0.0001 ⇓living p = 0.004 ⇓living p = 0.01 ⇑living p < 0.0001
Figure 1: Graphical summary, representing associations among the mRNA expression of the analyzed genes and clinical-pathological
variables. The red boxes indicate higher expression levels, the blue boxes indicate lower expression levels, and orange boxes are indicative
of mixed associations. “Lum” stands for luminal and “IHC” for immunohistochemistry. IHC data are defined as positive or negative
according to the already defined cutoffs.
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Figure 2: Box plot representing the mRNA expression levels (ratio of threshold cycles) of the genes that resulted to be significantly highly
expressed in LN- BC in comparison to LN+ BC: (a) AKT2, (b) AKT3, (c) PIK3CB, and (d) RB1 (Kruskal-Wallis test).
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2 − 9:79∗ratioPIK3CB − 1:69∗ratioAKT3+1:11∗ratioAKT
1 − 0:69 ∗ ratioRB1 to estimate the lymph node involve-
ment. The cutoff was defined by ROC analysis at -1.9057.
If the LN score was superior to that value, a lymph node
involvement was predicted. The ratio represents for each
gene included in the linear combination the value of the
relative quantification for the specific gene as determined
by RT real-time qPCR [14].
According to that calculation, we assessed BC-specific
survival and the development of later recurrences. The LN
involvement variable resulted to be significantly higher in
patients who developed later recurrences (p < 0:0001) and
discriminated among molecular subtypes (p < 0:0001) sepa-
rating luminal A from luminal B (p < 0:0001), and luminal
A from HER2 positive (non-luminal) (p < 0:0001) and
HER2 positive (non-luminal) from TN BC (p < 0:0001). LN
involvement increased from luminal A to HER2-positive
patients (non-luminal) but was lower in TN patients. That
variable also significantly increased with the tumor stage
and grade (p < 0:0001 for both) as shown in Figure 4.
3.4. Patient Overall and Cancer-Specific Survival. The expres-
sion levels of the candidate biomarkers were dichotomized
according to their median value to investigate their influence
on patients’ survival. The LN involvement variable was
dichotomized according to the cutoff obtained by ROC anal-
ysis. Over the entire cohort of BC patients, the overall sur-
vival seemed to be influenced by AKT1 (p = 0:02) and
AKT2 expression levels (p = 0:03), as shown in Figures 5(a)
and 5(b). Higher expression levels of those transcripts were
associated with shorter overall survival. Nonetheless, neither
AKT1 nor AKT2 expression confirmed to be independent
variables that influence patients’ survival as returned by the
multivariate Cox regression analysis including clinical and
pathological variables (age at diagnosis, stage, grade, and his-
tological type) and AKT1 and AKT2 status as covariates. The
LN involvement variable significantly influenced both overall
survival and cancer-specific survival (CSS) of BC patients
(Figures 5(c) and 5(d), respectively), as lower values of that
variable were associated with longer survival.
In LN- patients, RB1 and AKT3 seemed to have a protec-
tive effect on patients’ cancer-specific survival (p = 0:03 and
p = 0:01, respectively) as their higher expression levels were
associated with longer survival (in univariate analysis) as
shown in Figures 6(a) and 6(b). In multivariate Cox regres-
sion analysis, those two variables were not confirmed to
influence independently CSS. In LN+ patients, none of the
analyzed genes seemed to affect patients’ survival.
Patients’ survival was investigated for the analyzed genes
in the 4 molecular subtypes of BC, separately. A better
cancer-specific survival was found for higher levels of
AKT3 in luminal A BC patients (p = 0:0009, Figure 6(c)).
Further investigation on the role of AKT3 in our cohort
showed that estrogen- and progesterone-positive patients
displayed longer cancer-specific survival where higher
AKT3 levels (p = 0:006) were expressed supporting a possible
predictive role for Tamoxifen response (see Supplementary
file of results). Shorter cancer-specific survival was recorded
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Figure 3: Box plot representing the mRNA expression levels (ratio of threshold cycles) of the genes that resulted to be significantly highly
expressed in LN+ BC in comparison to LN- BC: (a) AKT1, (b) CDK2, (c) ERBB2, and (d) KRT8 (Kruskal-Wallis test).
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in luminal B patients displaying higher levels of AKT2
(p = 0:03) (Figure 6(d)). The LN involvement variable was
associated with CSS in luminal BC patients (p < 0:0001,
Figure 7(a)), both in luminal A (p = 0:0001, Figure 7(b))
and in luminal B (p = 0:03, Figure 7(c)) BC patients. Longer
survival for the high AKT3 status in luminal A patients was
confirmed by Cox multivariate analysis including as covar-
iates clinical and pathological variables (age at diagnosis,
stage, grade, and histological type) and LN involvement
variable, as reported in Table 2. The stage (p = 0:04) and
grade (p = 0:05, borderline), age at diagnosis (p = 0:05, bor-
derline), and AKT3 (p = 0:009) showed independent influ-
ence on patients’ survival.
4. Discussion
This study is aimed at investigating the role of the mRNA
expression levels of 9 genes belonging to signaling pathways
that control major cellular processes in a cohort of 305 young
patients (aged 55 years or less when diagnosed) affected by pri-
mary breast cancer for the molecular subtypes and clinical-
pathological variables. The choice of genes was mostly related
to the conclusions of our previous study [6] and lymph node
involvement. Our results highlight a complex pattern of
expression of the analyzed genes, which depends on lymph
node involvement as well as on the tumor stage, grade, and
molecular subtypes. The interplay of some analyzed genes in
lymph node involvement is highlighted in our regression
model, which points out a major contribution of AKT1 and
also of ERBB2 in metastatic lymph node involvement as well
as the protective effect of AKT3, PIK3CB, and RB1.
It is well known that LN involvement is a risk factor for
metastasis in BC and that there is a higher risk of progression
among patients with positive LN than expected in women
with negative LN [17]. The expression levels of most genes
analyzed in this study were differently represented in the
group of patients with and without LN involvement,
highlighting the difference of breast cancer for nodal involve-
ment. Nonetheless, the expression levels of most genes were
not independent variables affecting patients’ survival, sup-
porting a complex pattern in BC progression. Molecularly,
LN involvement resulted to be related to the contribution
of different genes at the primary tumor tissue level. Some of
those genes were more expressed in LN- patients, such as
PIK3CB, RB1, and AKT3, while some others in LN+ patients,
such as ERBB2 and AKT1, as highlighted also in our regres-
sion model.
In detail, AKT1, KRT8, ERBB2, and CDK2 were highly
expressed in the LN+ group, with no differences referred to
the number of involved lymph nodes (>3 or ≤3). Those
results were also valid considering only the luminal type of
cancers. The LN+ group, in our cohort, had higher frequen-
cies of HER2-positive (non-luminal) and luminal B tumors.
Among the aforementioned genes, AKT1 was also highly
expressed in recurrent BC patients and the same AKT1 with
ERBB2 and KRT8 was also highly expressed in patients with
breast cancer as a specific cause of death, likely because of the
higher rate of HER2-positive (non-luminal) and luminal B
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Figure 4: Box plot representing the distribution of the LN involvement variable as defined by the linear combination with respect of (a) BC stage,
(b) BC grade, and (c) molecular subtypes. HER2+: HER2 positive (non-luminal). (Kruskal-Wallis and extended Wilcoxon rank-sum tests).
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types among women with that expression pattern. In agree-
ment with us, both AKT1 and ERBB2 have already been
found to be highly expressed in ER+ recurrent breast cancer
[18] as possible genes involved in the mechanism of resis-
tance to Tamoxifen. Data on CDK2 are in agreement with
our previous study, which indicated that this cyclin-
dependent kinase was significantly higher in patients with
later recurrences [6]. Taking these observations into account,
we could assume that higher mRNA expression levels of
AKT1, CDK2, ERBB2, and KRT8molecules could be an indi-
cator of worse outcomes in our cohort of patients. We found,
surprisingly and in disagreement with our previous work [6],
that high KRT8 levels are indicative of poor outcome, despite
the KRT8 role in cell differentiation and in characterization
of luminal types of BC. KRT8 was highly expressed in LN+
BC and in patients dead from BC as it seemed to increase
with the size and stage of the tumor. Overall, the adverse
contribution of KRT8 in cancer is not novel and it seems
to find a possible explanation in the phosphorylation of
the protein. It has been shown, indeed, that phosphorylated
KRT8 is required and is sufficient to induce keratin reorga-
nization and consequently enhanced migration of human
epithelial tumor cells [19]. In BC, in particular, higher
KRT8 protein expression has been associated with lower
survival probability as shown in the Protein Atlas website
[20]. Also, Brotherick et al. detected higher KRT8 mRNA
levels in node-positive patients as opposed to node-negative
ones [21] which is in agreement with us. Additionally,
KRT8 mRNA, but not K18 and MGL, was overexpressed in
the blood of BC metastatic patients [22]. In our study, the
higher expression levels of KRT8 can characterize luminal
B BC, which are associated with a worse outcome among
luminal tumors.
Higher expression of RB1, AKT3, and PIK3CB was
detected in the LN- group and in patients without later recur-
rences. The results on RB1 agree with other studies that
reported the loss of RB to be correlated with advanced disease
and often with ER- subtypes of breast cancer [23]. Activation
of the PI3K/AKT signaling pathway is observed in up to 81%
of breast cancer patients [24]. In this study, we have analyzed
the expression of the PI3K 110β subunit and the 3 isoforms
of AKTs. The β isoform of the p110 catalytic subunit of
PI3K seems to overlap the structure and the enzymatic func-
tion of the α isoform, but p110α and p110β isoforms have
been reported to play distinct roles in cellular signaling,
growth, and oncogenic transformation [25]. In our study,
PI3K 110β expression was related to favorable prognostic
factors, because it significantly decreased with the tumor size
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Figure 5: Age-adjusted Kaplan-Meyer overall survival curves for AKT1 expression (a), AKT2 expression (b), and LN involvement variable (c)
in the entire cohort. Age-adjusted cancer-specific survival curves for LN involvement (d) in the entire cohort of patients. The gene expression
was dichotomized in low expression and high expression for the median value of each transcript; the cutoff value for the LN involvement
variable has been defined by ROC analysis. The graphs of the survivor function were adjusted to the mean age of patients (46.9 years).
CSS: cancer-specific survival (p values on the graph refer to the log-rank test).
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and grade; it was less expressed in LN-positive tumors, in
relapsing BC, and it was highly expressed in luminal A BC
and in living patients, supporting a protective role in BC pro-
gression. Our findings agree with the divergent roles of p110α
and p110β isoforms in mammary gland tumorigenesis [25].
According to the hypothesis of Untermark and coauthors, a
novel negative role of p110β in RTK signaling has been pro-
posed that comprises a competition model in which the less
active p110β competes with the more active p110α for
receptor-binding sites. Thereby, downtuning the level of lipid
kinase activity associated with receptors could explain the
positive effect of p110β on our cohort.
The three highly homologous AKT isoforms (i.e., AKT1,
AKT2, and AKT3) seem to play different or even functional
opposing roles in our cohort of patients. AKT1 was related
to shorter survival, and negative prognostic factors, mostly
independently of the LN involvement as highlighted in
Figure 1. Contrarily, AKT3 was associated with a good prog-
nosis, while AKT2 seemed to be associated to luminal B BC.
General activation of AKT has been shown to correlate with
shorter disease-free survival [26] and to be associated with
tumor progression [27]. However, emerging data indicate
that the three highly homologous AKT isoforms may play
different or even functional opposing roles in the regulation
of migration and invasion [27, 28]. The role of the three iso-
forms in breast cancer has been reported with divergent
results, because of the different methods used to detect them
and of the samples analyzed. Recently, in breast cancer,
AKT1 has been shown to be involved in the local tumor
growth while AKT2 in the distant tumor dissemination
[29]. In mouse and human breast cancer cells, the overactiva-
tion of AKT1 has been associated with ductal-like tumor
growth [30] but other studies showed that AKT1 could
inhibit epithelial-to-mesenchymal transition and BC metas-
tasis [31–33]. Our results come out in favor of a negative role
of AKT1 in BC. Regarding AKT2, our findings highlighted
higher expression levels in ER-positive LN-negative tumors,
but with a worse prognosis as shown by shorter survival in
luminal B BC patients. In agreement with us, AKT2 has
already been shown to modulate ER activity at multiple
levels, with a key role in the regulation of ER function and
its expression [34], and to promote cell migration and inva-
sion [35]. Furthermore, in our cohort, higher levels of
AKT2 were associated to lower tumor grade BC. This appar-
ent discrepancy is because AKT2 is highly expressed in lumi-
nal tumors which in our cohort are the only ones including
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Figure 6: Age-adjusted Kaplan-Meyer cancer-specific survival curves for RB1 expression in LN- patients (a), AKT3 expression in LN-
patients (b), AKT3 expression in luminal A patients (c), and AKT2 expression in luminal B patients (d). Graphs in (c) and (d) are
irrespective of the LN+ and/or LN- group. The gene expression was dichotomized in low expression and high expression for the median
value of each transcript. The graphs of the survivor function were adjusted to the mean age of patients (46.9 years). CSS: cancer-specific
survival (p values on the graph refer to the log-rank test).
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grade 1 BC. The functional role of AKT3 is the least exam-
ined which is therefore poorly understood. In our cohort of
luminal BC patients, AKT3 resulted to have a protective role,
even confirmed by the multivariate Cox regression. Our
results highlight that ER- and PR-positive BC patients with
higher AKT3 did not relapse during the follow-up and sur-
vived longer (see Supplementary file of results). Although it
is not a direct proof, AKT3 could represent a possible predic-
tive biomarker for Tamoxifen response, as all ER- and PR-
positive patients of our cohort at the time of diagnosis were
submitted to Tamoxifen treatment. No reports are support-
ing on that possible specific activity of AKT3 in ER- and
PR-positive BC patients, but only a study on the interaction
of AKT3 and estrogen function in MCF-7 cells where a con-
stitutively active form of AKT3 was induced [36]. Thus far,
AKT3 has been mostly studied in triple-negative breast can-
cers with conflicting results [24, 37–39]. Recently, Grottke
and coworkers have highlighted the beneficial effect of
AKT3 on BC cell lines. By knocking AKT3, but not AKT1
or AKT2, the authors promoted migration and the metastatic
potential in the MDA-MB-231 cell lines [24]. Suyama et al.
reported on a splice variant of AKT3, which promotes apo-
ptosis and suppresses mammary tumorigenesis [38]. All
those studies support our findings, although they are carried
out in TN breast cancer cells. Our observation of the different
contribution of AKTs in BC has been supported by gene
expression profiling analysis (GEPIA -http://gepia.cancer-
pku.cn) as shown in the supplementary file of results. In
detail, AKT3 was significantly highly expressed in normal
mammary glands if compared to BC tissue, an opposite trend
resulted for AKT1, and no difference was noticed for AKT2.
In our cohort, cancer-specific survival seems to be influ-
enced by a complex pattern by RB1 and AKT molecules,
depending on the LN involvement and molecular subtypes
(mostly luminal A and B). The reason could be the different
relationship and dependence of AKT isoforms with specific
effectors or activators as already shown for AKT2 and PTEN
and ER [34, 35].
Even though the mutational rate of most genes analyzed
in the present study is lower than 2.5% (see Supplementary
file of results) if compared with 27% of PIK3CA, we acknowl-
edge as a limitation in our study that the mutational status of
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Figure 7: Age-adjusted Kaplan-Meyer cancer-specific survival curves for LN involvement variable in luminal BC patients (a), luminal A BC
patients (b), and luminal B BC patients (c), irrespective of groups LN+ and/or LN-. LN involvement variable was dichotomized in low
expression and high expression for its cutoff value which has been defined by ROC analysis. The graphs of the survivor function were
adjusted to the mean age of patients (46.9 years). CSS: cancer-specific survival (p values on the graph refer to the log-rank test).
Table 2: Results of Cox multivariate analysis in luminal A patients.
Variables Hazard ratio 95% CI p
Histologic type 0.95 0.61-1.48 0.8
Stage 1.69 1.01-2.83 0.04
Grade 1.66 1.00-2.75 0.05
Age at diagnosis 1.06 1.00-1.13 0.05
AKT3 0.41 0.21-0.80 0.009
LN involvement variable 1.50 0.72-3.11 0.3
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PIK3CA has not been analyzed. Furthermore, no test set of
samples has been analyzed to validate the possible use of
the LN involvement variable in clinical practice and confirm
our findings.
In conclusion, our findings highlight that breast cancers
differed molecularly for LN involvement at the level of the
primary tumor. By comparing genes’ expression in these
two groups of tumors, we found that AKT3 and RB1 influ-
enced patients’ survival in LN-negative patients. For molecu-
lar subtyping of BC, AKT3 resulted to be an independent
favorable prognostic factor for luminal A BC patients and
could represent a possible candidate biomarker to Tamoxifen
response. Our results showed that high expression levels of
AKT3 are associated with a better outcome and longer
cancer-specific patients’ survival rates in those patients who
display the luminal A molecular class as well as in ER- and
PR-positive ones. AKT2 and AKT3 mRNA expression levels
can be useful in defining luminal BC with high and low risk
of relapse, AKT2 defining worse prognosis and AKT3 longer
survival. The possible interplay of the analyzed genes in
lymph node involvement has been described in our regres-
sion model, which is also associated with BC recurrence
and cancer-specific survival. Although it is not possible to
discuss its possible clinical use, it shows that the PI3K/AKT
pathway presents with the different and opposite contribu-
tions to lymph node involvement and disease progression.
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